Trifarotene | ||||
CAS NO.: | 895542-09-3 | |||
Chemical Formula: | C29H33NO4 | |||
Molecular Weight: | 459.6000 | |||
DMF&GMP status: | Please contact us for more details. | Description: |
Trifarotene is a topical retinoid cream used in the treatment of acne vulgaris that was first approved for use in the United States in October 2019. Retinoids are a class of medications structurally and functionally analogous to [vitamin A], though later generation retinoids such as trifarotene and [adapalene] bear little structural resemblance to vitamin A and are analogous only in function. Trifarotene is considered the first of the "fourth-generation" retinoids due to its uniquely selective activity - this selectivity appears to confer improved efficacy and reduced side effects as compared to older, less selective retinoids.
**The products protected by patents in this product catalog are used for laboratory analysis, research and development, and cannot be sold to any country or region with patent protection and for commercial purpose. If the resulting patent infringement risks and responsibilities will be borne by the buyer. |
|
Approvals | ||||
Active Ingredient | Dosage Form; Route | Strength | Proprietary Name | Applicant |
TRIFAROTENE | CREAM;TOPICAL | 0.005% | AKLIEF | GALDERMA LABORATORIES LP |
Patent Data | ||||
Patent No. | Patent Expiration | Drug Substance Claim | Drug Product Claim | Patent Use Code |
7807708 | 10/01/2026 | DS | DP | |
8227507 | 12/21/2025 | U-818 | ||
8470871 | 12/21/2025 | U-2639 | ||
9084778 | 05/30/2033 | DP | U-134 | |
Exclusive Data | ||||
Exclusivity Code | Exclusivity Expiration | |||
NCE | 10/04/2024 | |||